Analysts are so bullish on this global chip stock they keep naming it as their top pick
One stock frequently showed up in this month’s top calls from analysts, who are bullish on it as a play on artificial intelligence.
Elon Musk’s Neuralink implants brain tech in human patient for the first time
The in-human clinical trial marks just one step on Neuralink’s path toward commercialization.
S&P 500 closes little changed Tuesday as Fed rate decision looms: Live updates
Traders will watch for updates out of the Federal Open Market Committee’s two-day policy meeting that opened Tuesday.
DOJ and SEC unveil charges in $1.9 billion HyperFund cryptocurrency fraud
The HyperFund Ponzi scheme collapsed in 2022 after promising investors massive returns from crypto minining operations that didn’t exist, the DOJ says.
Pentagon says it is not seeking war with Iran after Jordan attack
U.S. Defense Secretary Lloyd Austin on Monday vowed the U.S. would take “all necessary actions” to defend its troops after a deadly drone attack in Jordan by Iran-backed militants, even as President Joe Biden’s administration stressed it was not seekin…
Reed Hastings sells $1.1 billion in Netflix shares
Netflix co-founder and executive chairman Reed Hastings has gifted two million shares of the streaming giant, according to a regulatory filing.
Lawmakers want U.S. to probe four Chinese firms involved in Ford battery plant — letter
A previously unreported letter said the four Chinese companies have direct ties to the Chinese military, Chinese Communist Party, North Korean government and alleged human rights abuses in China’s Xinjiang region.
These companies reporting earnings this week have a history of beating expectations, Bespoke says
These stocks can also pop on the back of their strong reports, history shows.
Retail return fraud is rising as consumers send back purchases in droves
Retail return fraud is rising, and companies face a tough balance of trying to keep customers loyal while cracking down on abuse of return policies.
This little-known genome editing stock is poised to surge more than 60%, JPMorgan says
According to analyst Eric Joseph, Beam is at the frontier of a rising theme for investors this year: therapeutics.
